GET DAILY SIGNALSQuanterix (QTRX) Q3 Results Show Narrowing Losses and Diagnostic Momentum
Key Takeaways
- Third-quarter revenue of $35.0 million beat the consensus estimate of roughly $33.85 million, though it declined about 13% from $40.2 million in the year-ago period.
- GAAP net loss per share narrowed to $0.46 from $0.73 a year earlier, while adjusted (non-GAAP) loss per share of $0.46 came in slightly wider than the $0.43 consensus.
- Adjusted gross margin expanded by 150 basis points to 47.4%, reflecting improved operational efficiency.
- LucentAD test volumes doubled as partnerships ramped, signaling momentum in the company's Alzheimer's disease diagnostics business.
- Cash usage improved markedly, with Quanterix ending the quarter holding roughly $81 million in cash and setting a year-end 2026 cash forecast of $70 million.
- Adjusted EBITDA showed a loss of $12.2 million, roughly flat versus $11.9 million a year earlier.
Why This Quarter Matters
Quanterix Corporation is a life sciences company focused on ultra-sensitive protein detection, operating across research tools and diagnostics. Its third-quarter report carries weight because the company has spent 2026 executing a transformation strategy aimed at restoring growth after a period of revenue declines. Investors are watching closely for evidence that a new leadership team, commercial reorganization, and scaling Alzheimer's disease diagnostics can translate into a durable revenue inflection. The quarter offered a test of that thesis, with sequential revenue growth, an improving year-over-year trend, and a narrowed net loss suggesting the business may be stabilizing even as profitability remains a work in progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Quanterix reported total revenue of $34.974 million for the third fiscal quarter ended September 30, 2026, compared with $40.233 million in the prior-year period. The figure topped consensus estimates of about $33.85 million. Product revenue was $25.193 million versus $26.151 million a year earlier, while service and other revenue was $9.359 million versus $14.036 million, and collaboration and license revenue rose to $0.422 million from $0.046 million.
On the bottom line, GAAP net loss was $21.591 million, or $0.46 per share, improved from a net loss of $33.517 million, or $0.73 per share, in the same quarter last year. Adjusted (non-GAAP) loss per share was $0.46, which was wider than the $0.43 consensus estimate. Adjusted gross margin improved to 47.4% from 45.9%, and adjusted EBITDA showed a loss of $12.2 million versus $11.9 million a year earlier.
Market Reaction and Investor Sentiment
Shares of QTRX slipped about 3.45% to $2.80 in premarket trading following the release, from a prior close of $2.90, as the wider-than-expected adjusted loss per share appeared to weigh on sentiment despite the revenue beat. The stock has been under pressure through 2026, down roughly 54% year-to-date as of the earnings period, reflecting investor caution around the company's transformation. Wall Street's consensus rating stands at Hold with an average price target of about $3.25. The market's response suggests investors are balancing encouraging diagnostics momentum and improved cash efficiency against persistent losses and top-line contraction.
Forward Outlook and Key Factors to Monitor
Management pointed to "initial signs of restoring growth," with third-quarter revenue up 6.3% sequentially and the year-over-year decline narrowing to roughly 1%. Investors will be watching whether this trajectory holds in the coming quarters.
One key monitor is the Alzheimer's disease diagnostics business, where LucentAD test volumes doubled during the quarter. Continued partnership expansion and clinical credibility for the LucentAD test remain central to the company's growth narrative.
Cost discipline is another focus. Adjusted gross margin improved, and cash usage fell sharply from the prior-year period, which had included significant acquisition-related outflows. The company ended the quarter with about $81 million in cash and guided to $70 million by year-end, a figure investors will track as a measure of runway.
Finally, watch the core research tools business, including Accelerator Lab bookings, which grew by a mid-teens percentage for a second straight quarter, and near-record Spatial consumables. How these demand signals evolve, alongside progress toward IVD readiness, will help determine whether Quanterix can convert its turnaround momentum into sustained revenue growth.
How Tickeron’s AI Tools Fit Into My Research
When I want to compare setups across the diagnostics space or spot emerging signals quickly, I turn to Tickeron’s AI Screener. It lets me filter by fundamentals, technical patterns, and performance metrics in one place, which helps me stay efficient without replacing my own analysis. The tool surfaces ideas that I can then review in more detail on my own.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for QTRX turns positive, indicating new upward trend
QTRX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 78 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for QTRX just turned positive on November 09, 2026. Looking at past instances where QTRX's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
QTRX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QTRX crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 116 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for QTRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 24 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 53 cases where QTRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
QTRX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. QTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of protein diagnostic platform
Industry MedicalNursingServices
Advertisement